Increased rejection rates in cardiac transplant associated with dexamethasone

Steroids

Volumn 73, Issue 4, 2008, Pages 441-448

  Cochrane, Adam B ^a   Husain, Aliya N ^a   Anderson, Allen S ^a   Kim, Antony Y ^a   Fedson, Savitri E ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Cardiac transplant; Glucocorticoids; Immunosuppression

Indexed keywords

BASILIXIMAB; CYCLOSPORIN A; DEXAMETHASONE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CARDIAC GRAFT REJECTION; CLINICAL ARTICLE; DISEASE CLASSIFICATION; DRUG DOSE REDUCTION; DRUG PULSE THERAPY; DRUG SUBSTITUTION; FEMALE; GRAFT RECIPIENT; HEART MUSCLE BIOPSY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; RETROSPECTIVE STUDY; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; DEXAMETHASONE; FEMALE; GLUCOCORTICOIDS; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSION; MALE; METHYLPREDNISOLONE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 39549088492     PISSN: 0039128X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.steroids.2007.12.019     Document Type: Article

References (31)

1. Lindenfeld J., Miller G.G., Shakar S.F., Zolty R., Lowes B.D., Wolfel E.E., et al. Drug therapy in the heart transplant recipient. Part II. Immunosuppressive drugs. Circulation 110 December 21 (25) (2004) 3858-3865
2. Arizon J.M., Anguita M., Valles F., Lopez-Rubio F., Lopez-Granados A., Casares J., et al. A randomized study comparing deflazacort and prednisone in heart transplant patients. J Heart Lung Transplant 12 September-October (5) (1993) 864-868
3. Felkel T.O., Smith A.L., Reichenspurner H.C., LaFleur B., Lutz J.F., Kanter K.R., et al. Survival and incidence of acute rejection in heart transplant recipients undergoing successful withdrawal from steroid therapy. J Heart Lung Transplant. 21 May (5) (2002) 530-539
4. Park M.H., Starling R.C., Ratliff N.B., McCarthy P.M., Smedira N.S., Pelegrin D., et al. Oral steroid pulse without taper for the treatment of asymptomatic moderate cardiac allograft rejection. J Heart Lung Transplant 18 December (12) (1999) 1224-1227
5. Czock D., Keller F., Rasche F.M., and Haussler U. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet 44 1 (2005) 61-98
6. Rhen T., and Cidlowski J.A. Antiinflammatory action of glucocorticoids-new mechanisms for old drugs. N Engl J Med 353 October 20 (16) (2005) 1711-1723
7. Migita K., Eguchi K., Kawabe Y., Nakamura T., Shirabe S., Tsukada T., et al. Apoptosis induction in human peripheral blood T lymphocytes by high-dose steroid therapy. Transplantation 63 February 27 (4) (1997) 583-587
8. Newton R. Molecular mechanisms of glucocorticoid action: what is important?. Thorax 55 July (7) (2000) 603-613
9. Brostjan C., Anrather J., Csizmadia V., Stroka D., Soares M., Bach F.H., et al. Glucocorticoid-mediated repression of NFkappaB activity in endothelial cells does not involve induction of IkappaBalpha synthesis. J Biol Chem 271 August 9 (32) (1996) 19612-19616
10. Christ M., and Wehling M. Cardiovascular steroid actions: swift swallows or sluggish snails?. Cardiovasc Res 40 October (1) (1998) 34-44
11. Barnes P.J., and Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 336 April 10 (15) (1997) 1066-1071
12. Mager D.E., Moledina N., and Jusko W.J. Relative immunosuppressive potency of therapeutic corticosteroids measured by whole blood lymphocyte proliferation. J Pharm Sci 92 July (7) (2003) 1521-1525
13. Mager D.E., Pyszczynski N.A., and Jusko W.J. Integrated QSPR-pharmacodynamic model of genomic effects of several corticosteroids. J Pharm Sci 92 April (4) (2003) 881-889
14. Losel R.M., Falkenstein E., Feuring M., Schultz A., Tillmann H.C., Rossol-Haseroth K., et al. Nongenomic steroid action: controversies, questions, and answers. Physiol Rev 83 July (3) (2003) 965-1016
15. Falkenstein E., and Wehling M. Nongenomically initiated steroid actions. Eur J Clin Invest 30 December (Suppl. 3) (2000) 51-54
16. Schmidt B.M., Gerdes D., Feuring M., Falkenstein E., Christ M., and Wehling M. Rapid, nongenomic steroid actions: A new age?. Front Neuroendocrinol 21 January (1) (2000) 57-94
17. Falkenstein E., Norman A.W., and Wehling M. Mannheim classification of nongenomically initiated (rapid) steroid action(s). J Clin Endocrinol Metab 85 May (5) (2000) 2072-2075
18. Wehling M. Specific, nongenomic actions of steroid hormones. Annu Rev Physiol 59 (1997) 365-393
19. Hafezi-Moghadam A., Simoncini T., Yang Z., Limbourg F.P., Plumier J.C., Rebsamen M.C., et al. Acute cardiovascular protective effects of corticosteroids are mediated by non-transcriptional activation of endothelial nitric oxide synthase. Nat Med 8 May (5) (2002) 473-479
20. Losel R., and Wehling M. Nongenomic actions of steroid hormones. Nat Rev Mol Cell Biol 4 January (1) (2003) 46-56
21. Falkenstein E., Tillmann H.C., Christ M., Feuring M., and Wehling M. Multiple actions of steroid hormones-a focus on rapid, nongenomic effects. Pharmacol Rev 52 December (4) (2000) 513-556
22. Buttgereit F., Brand M.D., and Burmester G.R. Equivalent doses and relative drug potencies for non-genomic glucocorticoid effects: a novel glucocorticoid hierarchy. Biochem Pharmacol 58 July 15 (2) (1999) 363-368
23. Holzknecht Z.E., Kuypers K.L., Plummer T.B., Williams J., Bustos M., Gores G.J., et al. Apoptosis and cellular activation in the pathogenesis of acute vascular rejection. Circ Res 91 December 13 (12) (2002) 1135-1141
24. Parolari A., Rubini P., Cannata A., Bonati L., Alamanni F., Tremoli E., et al. Endothelial damage during myocardial preservation and storage. Ann Thorac Surg 73 February (2) (2002) 682-690
25. Frangogiannis N.G., Mendoza L.H., Lindsey M.L., Ballantyne C.M., Michael L.H., Smith C.W., et al. IL-10 is induced in the reperfused myocardium and may modulate the reaction to injury. J Immunol 165 September 1 (5) (2000) 2798-2808
26. Verrier A.D. Activation of the endothelium in cardiac allografts. J Heart Lung Transplant 23 September (Suppl. 9) (2004) S229-S233
27. Taylor D.O., Edwards L.B., Boucek M.M., Trulock E.P., Keck B.M., and Hertz M.I. The Registry of the International Society for Heart and Lung Transplantation: twenty-first official adult heart transplant report-2004. J Heart Lung Transplant 23 July (7) (2004) 796-803
28. Davies T.H., Ning Y.M., and Sanchez E.R. Differential control of glucocorticoid receptor hormone-binding function by tetratricopeptide repeat (TPR) proteins and the immunosuppressive ligand FK506. Biochemistry 44 February 15 (6) (2005) 2030-2038
29. Ptachcinski R.J., Venkataramanan R., Burckart G.J., Hakala T.R., Rosenthal J.T., Carpenter B.J., et al. Cyclosporine-high-dose steroid interaction in renal transplant recipients: assessment by HPLC. Transplant Proc 19 February (1 Pt 2) (1987) 1728-1729
30. Klintmalm G., Sawe J., Ringden O., von Bahr C., and Magnusson A. Cyclosporine plasma levels in renal transplant patients. Association with renal toxicity and allograft rejection. Transplantation 39 February (2) (1985) 132-137
31. Shimada T., Terada A., Yokogawa K., Kaneko H., Nomura M., Kaji K., et al. Lowered blood concentration of tacrolimus and its recovery with changes in expression of CYP3A and P-glycoprotein after high-dose steroid therapy. Transplantation 74 November 27 (10) (2002) 1419-1424